Akebia Therapeutics Inc. (NASDAQ:AKBA) traded with an addition of $0.04 to close at $1.16on Friday, an upside of 4.02 percent. An average of 1,145,763 shares of common stock have been traded in the last five days. There was a fall of -$0.0200 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 1,185,501 shares traded, while the 50-day average volume stands at 1,761,600.
AKBA stock has decreased by -16.79% in the last month. The company shares reached their 1-month lowest point of $1.1000 on 09/25/23. With the stock rallying to its 52-week high on 08/01/23, shares of the company touched a low of $0.24 and a high of $1.84 in 52 weeks. It has reached a new high 14 times so far this year and achieved 101.91% or $0.5830 in price. In spite of this, the price is down -36.68% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AKBA stock investors should be aware that Akebia Therapeutics Inc. (AKBA) stock had its last reported insider trading activity 127 days ago on May 25. In this transaction, the insider spent $116,760. SVP, Chief Legal Officer, Hadas Nicole R., disposed of 63,186 shares at a price of $1.22 on May 25. The insider now owns more than $77,270 worth of shares. Prior to that, SVP, Chief Medical Officer Burke Steven Keith went on to Sale 63,567 shares at $1.07 each on May 16. An amount of $67,890 was transacted.
Valuation Metrics
Akebia Therapeutics Inc. (AKBA) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is 0.88. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.09.
Financial Health
The quick ratio of Akebia Therapeutics Inc. for the three months ended June 29 was 1.06, and the current ratio was 1.28, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $206.92 million compared to revenue of $292.48 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Akebia Therapeutics Inc.’s return on assets was -25.39%.
Earnings Surprise
For the three-month period that ended June 29, Akebia Therapeutics Inc. had $18.49 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$11.17 million in the quarter, while revenues of -$26.22 million were grew 362.13%. The analyst consensus anticipated Akebia Therapeutics Inc.’s latest quarter earnings to come in at -$0.02 per share, but it turned out to be -$0.06, a -200.00% surprise. For the quarter, EBITDA amounted to $0.41 million. Shareholders own equity worth $188.31 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Akebia Therapeutics Inc. (AKBA) price momentum. RSI 9-day as of the close on 28 September was 43.12%, suggesting the stock is Neutral, with historical volatility in this time frame at 43.20%.
As of today, AKBA’s price is $1.1460 -1.69% or -$0.0200 from its 5-day moving average. AKBA is currently trading -16.55% lower than its 20-day SMA and +9.43% higher than its 100-day SMA. However, the stock’s current price level is -5.69% below the SMA50 and +210.99% above the SMA200.
The stochastic %K and %D were 18.42% and 19.57%, respectively, and the average true range (ATR) was 0.0799. With the 14-day stochastic at 26.09% and the average true range at 0.0889, the RSI (14) stands at 43.95%. The stock has reached -0.0222 on the 9-day MACD Oscillator while the 14-day reading was at -0.0517.
Analyst Ratings
H.C. Wainwright upgraded Akebia Therapeutics Inc. (NASDAQ: AKBA) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Akebia Therapeutics Inc. (AKBA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AKBA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is AKBA’s price target for the next 12 months?
Analysts predict a range of price targets between $3.75 and $4.00, with a median target of $3.88. Taking a look at these predictions, the average price target given by analysts for Akebia Therapeutics Inc. (AKBA) stock is $3.88.
